Douglas A. Levine

Douglas A. Levine is a Senior Principal Scientist in Early Oncology Development at Merck Research Labs. He previously served as Director of Gynecologic Oncology at Perlmutter Comprehensive Cancer Center of New York University Langone Health in New York City. He received his M.D. from Mount Sinai School of Medicine and completed his residency at Mount Sinai Medical Center and a fellowship at Memorial Sloan Kettering. In addition to his clinical practice, Dr. Levine was Head of the Gynecology Research Laboratory, where he studies cancer prevention, precision medicine, and rare tumors with unmet needs. He served as the translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. He discovered universal mutations in SMARCA4 that drive small cell carcinoma of the ovary, hypercalcemic type. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women’s health. Dr. Levine has been very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He served as co-chair of the ovarian, endometrial, uterine carcinosarcoma, and Pan-GYN disease working groups. He has authored or co-authored more than 235 peer-reviewed articles and two textbooks. He most recently served as Assistant Dean of the Department of Defense Ovarian Cancer Academy and Chair of the NCI Cancer Biomarkers Study Section. He was also Chair of Cancer Prevention for NRG Oncology Clinical Trials Network.